Spots Global Cancer Trial Database for recurrent childhood acute myeloid leukemia
Every month we try and update this database with for recurrent childhood acute myeloid leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia | NCT01229956 | Leukemia | DNA methylation... gene expression... microarray anal... reverse transcr... laboratory biom... | 1 Year - 18 Years | Children's Oncology Group | |
| Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | NCT00052520 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... B-cell Adult Ac... B-cell Childhoo... Childhood Chron... Childhood Myelo... Chronic Myelomo... Essential Throm... Polycythemia Ve... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... T-cell Adult Ac... T-cell Childhoo... | therapeutic all... aldesleukin peripheral bloo... allogeneic bone... laboratory biom... gene expression... immunologic tec... flow cytometry polymerase chai... cytogenetic ana... staining method | - | Fred Hutchinson Cancer Center | |
| Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia | NCT00003868 | Leukemia | cyclophosphamid... methotrexate allogeneic bone... peripheral bloo... iodine I 131 mo... radiation thera... | 2 Years - 55 Years | Fred Hutchinson Cancer Center | |
| FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia | NCT00053963 | Blastic Phase C... Childhood Centr... Childhood Choro... Childhood Chron... Childhood Crani... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Spina... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chro... Relapsing Chron... Unspecified Chi... | romidepsin | - 21 Years | National Cancer Institute (NCI) | |
| Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia | NCT00003735 | Leukemia | topotecan hydro... | - 21 Years | Children's Oncology Group | |
| STI571 in Treating Patients With Recurrent Leukemia | NCT00004932 | Leukemia | imatinib mesyla... | - 21 Years | Children's Oncology Group | |
| Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant | NCT01640301 | Recurrent Adult... Recurrent Child... Secondary Acute... Therapy-Related... Donor Hematopoietic C... HLA-A*0201 Posi... Recurrent Acute... | Aldesleukin Cyclophosphamid... Fludarabine Pho... Laboratory Biom... WT1-Sensitized ... | - | Fred Hutchinson Cancer Center | |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | NCT00445744 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child... | cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema... | - 65 Years | Fred Hutchinson Cancer Center | |
| Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia | NCT00357565 | Leukemia Myelodysplastic... Childhood Acute... Recurrent Child... Secondary Acute... Childhood Acute... Previously Trea... Secondary Myelo... Refractory Anem... Refractory Anem... Refractory Anem... De Novo Myelody... Childhood Myelo... | filgrastim busulfan cyclosporine fludarabine pho... melphalan mycophenolate m... umbilical cord ... | - 3 Years | Masonic Cancer Center, University of Minnesota | |
| Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531 | NCT01407757 | Leukemia | DNA analysis gene expression... laboratory biom... pharmacogenomic... | - 29 Years | Children's Oncology Group | |
| Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia | NCT00006462 | Leukemia | gemcitabine hyd... | - 21 Years | Children's Oncology Group | |
| Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia | NCT00008697 | Leukemia | arsenic trioxid... | - | Washington University School of Medicine | |
| Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD | NCT00914940 | Graft Versus Ho... Leukemia Myelodysplastic... | Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted... | 14 Years - 55 Years | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | NCT00053131 | Leukemia | filgrastim sargramostim cytarabine mitoxantrone hy... | 15 Years - | Roswell Park Cancer Institute | |
| Detection of Residual Disease in Children Receiving Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT00003790 | Leukemia Myelodysplastic... | polymerase chai... flow cytometry | - 21 Years | Children's Oncology Group | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia | NCT00008190 | Leukemia | aldesleukin filgrastim busulfan cyclophosphamid... etoposide melphalan peripheral bloo... | - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia | NCT00003758 | Leukemia | cytarabine idarubicin allogeneic bone... autologous bone... peripheral bloo... | 15 Years - 60 Years | National Cancer Institute (NCI) | |
| Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | NCT00027820 | Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Myelo... Childhood Renal... Chronic Myelomo... Clear Cell Rena... de Novo Myelody... Metastatic Rena... Previously Trea... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Chil... Refractory Chro... Renal Medullary... Type 1 Papillar... Type 2 Papillar... Untreated Adult... Untreated Adult... Untreated Child... | Fludarabine Pho... Total-Body Irra... Peripheral Bloo... Nonmyeloablativ... Cyclosporine Mycophenolate M... | - | Fred Hutchinson Cancer Center | |
| BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia | NCT00006213 | Adult Acute Pro... Blastic Phase C... Childhood Myelo... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... | BMS-214662 pharmacological... laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| Raltitrexed in Treating Children With Refractory Acute Leukemia | NCT00003528 | Recurrent Child... Recurrent Child... | raltitrexed | - 21 Years | National Cancer Institute (NCI) | |
| Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia | NCT00021242 | Leukemia | docetaxel | - 21 Years | Children's Oncology Group | |
| Biomarkers in Predicting Response to Treatment in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia | NCT01321385 | Leukemia | laboratory biom... study of socioe... | - 21 Years | Children's Oncology Group | |
| Ex Vivo Drug Sensitivity Testing and Mutation Profiling | NCT03860376 | Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chil... Refractory Chil... Refractory Chil... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chro... | 1 Day - 21 Years | Florida International University | ||
| Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML | NCT00871689 | Leukemia | aldesleukin cyclophosphamid... fludarabine pho... umbilical cord ... total-body irra... | - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Chemotherapy in Treating Patients Who Have Hematologic Cancer | NCT00004047 | Leukemia Myelodysplastic... | exatecan mesyla... | - | Daiichi Sankyo | |
| Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD | NCT00914940 | Graft Versus Ho... Leukemia Myelodysplastic... | Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted... | 14 Years - 55 Years | Fred Hutchinson Cancer Center | |
| Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant | NCT03537599 | Minimal Residua... Recurrent Acute... Recurrent Adult... Recurrent Child... | Daratumumab Donor Lymphocyt... Laboratory Biom... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | NCT00445744 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child... | cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema... | - 65 Years | Fred Hutchinson Cancer Center | |
| Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia | NCT00009698 | Leukemia | aldesleukin | - 21 Years | Children's Oncology Group | |
| Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | NCT01005277 | Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Childhood Acute... Childhood Acute... Childhood Acute... Recurrent Child... Recurrent Child... Secondary Acute... | Laboratory Biom... | - | Children's Oncology Group | |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children | NCT01858740 | Accelerated Pha... Acute Biphenoty... Acute Leukemia ... Acute Undiffere... Adult Acute Lym... Adult Acute Mye... Blast Phase Chr... Childhood Acute... Childhood Acute... Chronic Myeloge... Myelodysplastic... Myelodysplastic... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Adul... Refractory Chil... | Allogeneic Hema... Fludarabine Pho... Laboratory Biom... Methotrexate Peripheral Bloo... T Cell-Depleted... Tacrolimus Thiotepa Total-Body Irra... | - 21 Years | Fred Hutchinson Cancer Center | |
| Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | NCT00112567 | Leukemia Myelodysplastic... | fludarabine pho... thiotepa peripheral bloo... radiation thera... | - 20 Years | Fred Hutchinson Cancer Center | |
| Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT00119366 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Myelo... Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Acute... Secondary Myelo... | iodine I 131 mo... fludarabine pho... total-body irra... allogeneic hema... peripheral bloo... cyclosporine mycophenolate m... laboratory biom... | 16 Years - 50 Years | Fred Hutchinson Cancer Center | |
| Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer | NCT00290641 | Chronic Myelopr... Leukemia Lymphoma Myelodysplastic... | filgrastim graft-versus-tu... cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... radiation thera... | - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases | NCT00450983 | Graft Versus Ho... Leukemia Myelodysplastic... | muromonab-CD3 natural killer ... fludarabine pho... methotrexate thiotepa gene expression... flow cytometry immunologic tec... allogeneic hema... in vitro-treate... total-body irra... | - 45 Years | Fred Hutchinson Cancer Center | |
| Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome | NCT00002547 | Leukemia Myelodysplastic... | busulfan cyclophosphamid... cyclosporine cytarabine methotrexate allogeneic bone... syngeneic bone ... | - 60 Years | Barbara Ann Karmanos Cancer Institute | |
| Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia | NCT00002912 | Leukemia | etoposide mitoxantrone hy... valspodar | - 21 Years | National Cancer Institute (NCI) | |
| Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant | NCT03537599 | Minimal Residua... Recurrent Acute... Recurrent Adult... Recurrent Child... | Daratumumab Donor Lymphocyt... Laboratory Biom... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia | NCT00006213 | Adult Acute Pro... Blastic Phase C... Childhood Myelo... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... | BMS-214662 pharmacological... laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia | NCT00006462 | Leukemia | gemcitabine hyd... | - 21 Years | Children's Oncology Group | |
| Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia | NCT00003868 | Leukemia | cyclophosphamid... methotrexate allogeneic bone... peripheral bloo... iodine I 131 mo... radiation thera... | 2 Years - 55 Years | Fred Hutchinson Cancer Center | |
| Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia | NCT01076569 | Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Recurrent Child... Untreated Child... | laboratory biom... | - 21 Years | Children's Oncology Group | |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD | NCT02220985 | Accelerated Pha... Acute Biphenoty... Acute Leukemia ... Acute Undiffere... Allogeneic Hema... Blast Phase Chr... Blastic Plasmac... Childhood Acute... Childhood Acute... Donor Lymphoblastic L... Myelodysplastic... Myelodysplastic... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Child... Recurrent Child... Recurrent Chron... Refractory Acut... Refractory Acut... Acute Lymphobla... Acute Myeloid L... | Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Methotrexate Mycophenolate M... Peripheral Bloo... Peripheral Bloo... Tacrolimus Thiotepa Total-Body Irra... | - 60 Years | Fred Hutchinson Cancer Center | |
| Biomarkers in Samples From Patients With Down Syndrome and Acute Megakaryoblastic Leukemia | NCT01139307 | Leukemia | cell culture pr... laboratory biom... | - | Children's Oncology Group | |
| Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies | NCT00544466 | Leukemia Myelodysplastic... | fludarabine pho... melphalan allogeneic hema... intensity-modul... | 7 Years - | City of Hope Medical Center | |
| Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia | NCT00666588 | Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Recurrent Adult... Recurrent Child... Secondary Acute... | idarubicin cytarabine bortezomib etoposide laboratory biom... | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | NCT01445080 | Blastic Phase Childhood Acute... Childhood Chron... Childhood Solid... Chronic Myeloge... Juvenile Myelom... Philadelphia Ch... Recurrent Child... Recurrent Child... Recurrent Disea... | Laboratory Biom... Pharmacological... Sorafenib Tosyl... | 2 Years - 21 Years | National Cancer Institute (NCI) | |
| Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes | NCT00028899 | Leukemia Myelodysplastic... | asparaginase cytarabine gemtuzumab ozog... mitoxantrone hy... | - 21 Years | Children's Oncology Group | |
| Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer | NCT00534430 | Leukemia Myelodysplastic... | busulfan cyclosporine etoposide mycophenolate m... allogeneic bone... allogeneic hema... peripheral bloo... total-body irra... | 16 Years - 50 Years | City of Hope Medical Center | |
| Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia | NCT02791919 | CNS 2a CNS 2b CNS 2c CNS1 Recurrent Adult... Recurrent Child... | Cytarabine Filgrastim Fludarabine Pho... Laboratory Biom... Pharmacological... WEE1 Inhibitor ... | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant | NCT00107354 | Leukemia Myelodysplastic... | aldesleukin therapeutic all... therapeutic aut... cytarabine etoposide mitoxantrone hy... allogeneic bone... peripheral bloo... | 14 Years - | Fred Hutchinson Cancer Center | |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | NCT00079404 | Acute Undiffere... Recurrent Child... Recurrent Child... Secondary Acute... Unspecified Chi... | tanespimycin | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children | NCT01858740 | Accelerated Pha... Acute Biphenoty... Acute Leukemia ... Acute Undiffere... Adult Acute Lym... Adult Acute Mye... Blast Phase Chr... Childhood Acute... Childhood Acute... Chronic Myeloge... Myelodysplastic... Myelodysplastic... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Adul... Refractory Chil... | Allogeneic Hema... Fludarabine Pho... Laboratory Biom... Methotrexate Peripheral Bloo... T Cell-Depleted... Tacrolimus Thiotepa Total-Body Irra... | - 21 Years | Fred Hutchinson Cancer Center | |
| Bone Marrow Transplantation in Treating Patients With Leukemia | NCT00006451 | Graft Versus Ho... Leukemia Lymphoma | anti-thymocyte ... cyclophosphamid... cyclosporine methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT00725062 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | CD4+CD25+ regul... allogeneic hema... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT | NCT02728700 | Adult Hodgkin L... Adult Myelodysp... Blast Phase Chr... Childhood Chron... Childhood Hodgk... Childhood Myelo... Chronic Phase C... Myelofibrosis Primary Myelofi... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Chron... Refractory Chro... Refractory Non-... | Allogeneic Hema... Laboratory Biom... Mycophenolate M... Sirolimus | 3 Years - 30 Years | Stanford University | |
| AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia | NCT01798901 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Recurrent Child... Secondary Acute... Untreated Adult... | HDAC inhibitor ... decitabine laboratory biom... pharmacological... | 3 Years - | Ohio State University Comprehensive Cancer Center | |
| Topotecan in Treating Children With Refractory Leukemia | NCT00002705 | Leukemia | topotecan hydro... | - 20 Years | National Cancer Institute (NCI) | |
| Aminopterin in Treating Patients With Refractory Leukemia | NCT00003305 | Leukemia | aminopterin leucovorin calc... | - | National Cancer Institute (NCI) | |
| Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation | NCT00002456 | Graft Versus Ho... Leukemia Lymphoma | cyclosporine methotrexate allogeneic bone... | - | Fred Hutchinson Cancer Center | |
| Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant | NCT00052598 | Accelerated Pha... Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Childhood Chron... Childhood Myelo... Recurrent Adult... Recurrent Child... Relapsing Chron... Secondary Acute... | therapeutic all... aldesleukin laboratory biom... flow cytometry | - | Fred Hutchinson Cancer Center | |
| Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02642965 | Acute Myeloid L... Recurrent Child... Secondary Acute... | Cytarabine Filgrastim Fludarabine Pho... Laboratory Biom... Liposome-encaps... Pharmacological... | 1 Year - 21 Years | Children's Oncology Group | |
| Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia | NCT00003178 | Leukemia | filgrastim cladribine idarubicin | - 21 Years | Children's Oncology Group | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia | NCT00008190 | Leukemia | aldesleukin filgrastim busulfan cyclophosphamid... etoposide melphalan peripheral bloo... | - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT00002805 | Leukemia | filgrastim cladribine cytarabine etoposide methotrexate mitoxantrone hy... therapeutic hyd... allogeneic bone... autologous bone... peripheral bloo... low-LET cobalt-... low-LET electro... low-LET photon ... | - 21 Years | Children's Oncology Group | |
| Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT00725062 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | CD4+CD25+ regul... allogeneic hema... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML | NCT00871689 | Leukemia | aldesleukin cyclophosphamid... fludarabine pho... umbilical cord ... total-body irra... | - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Tipifarnib in Treating Young Patients With Refractory Leukemia | NCT00022451 | Leukemia | tipifarnib | - 21 Years | National Institutes of Health Clinical Center (CC) | |
| Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant | NCT01640301 | Recurrent Adult... Recurrent Child... Secondary Acute... Therapy-Related... Donor Hematopoietic C... HLA-A*0201 Posi... Recurrent Acute... | Aldesleukin Cyclophosphamid... Fludarabine Pho... Laboratory Biom... WT1-Sensitized ... | - | Fred Hutchinson Cancer Center | |
| Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | NCT00112567 | Leukemia Myelodysplastic... | fludarabine pho... thiotepa peripheral bloo... radiation thera... | - 20 Years | Fred Hutchinson Cancer Center | |
| Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer | NCT01132547 | Cancer | cyproheptadine ... placebo | 2 Years - 21 Years | University of South Florida | |
| Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation | NCT01371656 | Acute Leukemias... Bacterial Infec... Diarrhea Fungal Infectio... Musculoskeletal... Neutropenia Recurrent Child... Recurrent Child... Secondary Acute... Untreated Child... | levofloxacin | 6 Months - 21 Years | Children's Oncology Group | |
| Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant | NCT00526292 | Leukemia Myelodysplastic... | natural killer ... cyclophosphamid... fludarabine | - 120 Years | Memorial Sloan Kettering Cancer Center | |
| DNA Analysis of Bone Marrow and Blood Samples From Young Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | NCT00899652 | Leukemia | Southern blotti... chromosomal tra... cytogenetic ana... gene rearrangem... mutation analys... | - 21 Years | Children's Oncology Group | |
| AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia | NCT01798901 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Recurrent Child... Secondary Acute... Untreated Adult... | HDAC inhibitor ... decitabine laboratory biom... pharmacological... | 3 Years - | Ohio State University Comprehensive Cancer Center | |
| Detection of Residual Disease in Children Receiving Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT00003790 | Leukemia Myelodysplastic... | polymerase chai... flow cytometry | - 21 Years | Children's Oncology Group | |
| Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia | NCT00003758 | Leukemia | cytarabine idarubicin allogeneic bone... autologous bone... peripheral bloo... | 15 Years - 60 Years | National Cancer Institute (NCI) | |
| Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome | NCT00005593 | Leukemia Myelodysplastic... | carboplatin fludarabine pho... topotecan hydro... | 12 Years - | Case Comprehensive Cancer Center | |
| Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT00008151 | Leukemia Myelodysplastic... | cyclosporine fludarabine pho... gemtuzumab ozog... methotrexate mycophenolate m... allogeneic bone... peripheral bloo... radiation thera... | - | Fred Hutchinson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
